Select your language

Hansjörg Riedwyl, CEO of ISS AG, will lead the breakout session #4 entitled “Artificial Intelligence & Medtech: between leaps in innovation and approval hurdles”.

The goal of this session is to provide insights into the current status of Artificial Intelligence in the medtech industry and to provide concrete ideas how to tackle the approval hurdles in order to encourage companies to include AI-considerations in their product strategies.

Daniel Diezi and Gabriel Krummenacher (Zühlke Group AG), as well as Kay-Uwe Clemens (Carl Zeiss Meditec) and Corne de Jong (Healios AG) will also actively participate to the present session.

More information and registration here.